Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

Journal of Pharmaceutical and Biomedical Analysis

Volumn 100, Issue , 2014, Pages 369-380

  Deja, Stanislaw ^a   Porebska, Irena ^b   Kowal, Aneta ^b   Zabek, Adam ^c   Barg, Wojciech ^b   Pawelczyk, Konrad ^b   Stanimirova, Ivana ^d   Daszykowski, Michal ^d   Korzeniewska, Anna ^b   Jankowska, Renata ^b   Mlynarz, Piotr ^c  

^a UNIVERSITY OF OPOLE   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d UNIVERSITY OF SILESIA   (Poland)

Author keywords

1H NMR spectroscopy; COPD chronic obstructive pulmonary disease; Lung cancer; Metabolic fingerprinting; Metabolomics

Indexed keywords

ACETIC ACID; ACETOACETIC ACID; CHOLINE; CITRIC ACID; CREATINE; GLYCEROL; GLYCOPROTEIN; ISOLEUCINE; LEUCINE; LIPID; LYSINE; MANNOSE; METHANOL; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; NON SMALL CELL LUNG CANCER; PARTIAL LEAST SQUARES REGRESSION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; LUNG; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; LUNG; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84908566336     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.08.020     Document Type: Article

References (65)

1. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/
2. http://www.cancerresearchuk.org/cancer-help/type/lung-cancer/treatment/statistics-and-outlook-for-lung-cancer#outcome
3. National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365(5):395-409.
4. Veronesi G., Maisonneuve P., Bellomi M., Rampinelli C., Durli I., Bertolotti R., Spaggiari L. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann. Intern. Med. 2012, 157(11):776-784.
5. Nanavaty P., Alvarez M.S., Alberts W.M. Lung cancer screening: advantages, controversies, and applications. Cancer Control 2014, 21(1):9-14.
6. Julian R.M., Ping Y., Stephen D.C., Steven E.S., Alex A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83(5):584-594.
7. Navada S., Lai P., Schwartz A.G., Kalemkerian G.P. Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (SEER) database. J. Clin. Oncol. 2006, 24(18_suppl):S7082. (Meeting Abstracts).
8. Santos E.S., Castrellon A., Blaya M., Raez L.E. Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2008, 8(12):1913-1929.
9. Punturieri A., Szabo E., Croxton T.L., Shapiro S.D., Dubinett S.M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J. Natl. Cancer Inst. 2009, 101(8):554-559.
10. Potton E., McCaughan F., Janes S.M. Chronic obstructive pulmonary disease and lung cancer. Respir. Med. 2009, 5(2):34-37.
11. Wang H., Yang L., Zou L., Huang D., Guo Y., Pan M., Tan Y., Zhong H., Ji W., Ran P., Zhong N., Lu J. Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in southern Chinese and a meta-analysis. PLoS ONE 2012, 7(9):e46144.
12. Yao H., Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr. Opin. Pharmacol. 2009, 9(4):375-383.
13. Petty T.L. Are COPD and lung cancer two manifestations of the same disease?. Chest 2005, 128(4):1895-1897.
14. Ardies C.M. Inflammation as cause for scar cancers of the lung. Integr. Cancer Ther. 2003, 2(3):238-246.
15. Brody J.S., Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc. Am. Thorac. Soc 2006, 3(6):535-537.
16. Vermaelen K., Brusselle G. Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. Pulm. Pharmacol. Ther. 2013, 26(5):544-554.
17. Powell H.A., Iyen-Omofoman B., Baldwin D.R., Hubbard R.B., Tata L.J. Chronic obstructive pulmonary disease and risk of lung cancer the importance of smoking and timing of diagnosis. J. Thorac. Oncol. 2013, 8(4):e34-e35.
18. Newby L.K., Storrow A.B., Gibler W.B., Garvey J.L., Tucker J. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001, 103(14):1832-1837.
19. Rocha C.M., Carrola J., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J. Proteome Res. 2011, 10(9):4314-4324.
20. Carrola J., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 2011, 10(1):221-230.
21. Duarte I.F., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours?. Virchows Arch. 2010, 457(6):715-725.
22. Jordan K.W., Adkins C.B., Su L., Halpern E.F., Mark E.J., Christiani D.C., Cheng L.L. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer 2010, 68(1):44-50.
23. Hori S., Nishiumi S., Kobayashi K., Shinohara M., Hatakeyama Y., Kotani Y., Hatano N., Maniwa Y., Nishio W., Bamba T., Fukusaki E., Azuma T., Takenawa T., Nishimura Y., Yoshida M. A metabolomic approach to lung cancer. Lung Cancer 2011, 74(2):284-292.
24. Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Humpfer E., Spraul M., Carreira I.M., Melo J.B., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J. Proteome Res. 2010, 9(1):319-332.
25. Wang L., Tang Y., Liu S., Mao S., Ling Y., Liu D., He X., Wang X. Metabonomic profiling of serum and urine by 1H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PLoS ONE 2013, 8(6):e65675.
26. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., van Weel C., Zielinski J. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care. Med. 2007, 176(6):532-555.
27. Goldstraw P. Lung and pleural tumours. International Association for the Study of Lung Cancer. Staging Manual in Thoracic Oncology 2009, 164. Editorial Rx Press, Florida. P. Goldstraw (Ed.).
28. Beckonert O., Keun H.C., Ebbels T.M., Bundy J., Holmes E., Lindon J.C., Nicholson J.K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2(11):2692-2703.
29. Smolinska A., Blanchet L., Buydens L.M., Wijmenga S.S. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal. Chim. Acta 2012, 750:82-97.
30. Savorani F., Tomasi G., Engelsen S.B. Icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J. Magn. Reson. 2010, 202(2):190-202.
31. Dieterle F., Ross A., Schlotterbeck G., Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1 H NMR metabonomics. Anal. Chem. 2006, 78(13):4281-4290.
32. Trygg J., Wold S. Orthogonal projections to latent structures (OPLS). J. Chemom. 2002, 16:119-128.
33. Xia J., Wishart D.S. MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res. 2010, 38:W71-W77.
34. Nicholson J.K., Foxall P.J., Spraul M., Farrant R.D., Lindon J.C. 750MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal. Chem. 1995, 67(5):793-811.
35. Westerhuis J.A., Hoefsloot H.C.J., Smit S., Vis D.J., Smilde A.K., van Velzen E.J.J., van Duijnhoven J.P.M., van Dorsten F.A. Assessment of PLS-DA cross validation. Metabolomics 2008, 4(1):81-88.
36. Kennard R.W., Stone L.A. Computed aided design of experiments. Technometrics 1969, 11:137-148.
37. Obuchowski N.A., Lieber M.L., F.H. Jr. Wians ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin. Chem. 2004, 50(7):1118-1125.
38. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39(4):561-577.
39. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., Yasui Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93(14):1054-1061.
40. Xia J., Broadhurst D.I., Wilson M., Wishart D.S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013, 280-299.
41. Cao M., Zhao L., Chen L., Xue W., Lin D. NMR-based metabolomic analysis of human bladder cancer. Anal. Sci. 2012, 28(5):451-456.
42. Wang L., Chen J., Chen L., Deng P., Bu Q., Xiang P., Li M., Lu W., Xu Y., Lin H., Wu T., Wang H., Hu J., Shao X., Cen X., Zhao Y.L. 1H-NMR based metabonomic profiling of human esophageal cancer tissue. Mol. Cancer 2013, 4:12-25.
43. Deja S., Dawiskiba T., Balcerzak W., Orczyk-Pawiłowicz M., Głód M., Pawełka D., Młynarz P. Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions. PLoS ONE 2013, 8(12):e84637.
44. Wen T., Gao L., Wen Z., Wu C., Tan C.S., Toh W.Z., Ong C.N. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol. Biosyst. 2013, 9(9):2370-2378.
45. Noguchi Y., Zhang Q.W., Sugimoto T., Furuhata Y., Sakai R., Mori M., Takahashi M., Kimura T. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am. J. Clin. Nutr. 2006, 83(2). 513S-9S.
46. Maeda J., Higashiyama M., Imaizumi A., Nakayama T., Yamamoto H., Daimon T., Yamakado M., Imamura F., Kodama K. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 2010, 10:690.
47. Shingyoji M., Iizasa T., Higashiyama M., Imamura F., Saruki N., Imaizumi A., Yamamoto H., Daimon T., Tochikubo O., Mitsushima T., Yamakado M., Kimura H. The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer. BMC Cancer 2013, 13:77.
48. Miyagi Y., Higashiyama M., Gochi A., Akaike M., Ishikawa T., Miura T., Saruki N., Bando E., Kimura H., Imamura F., Moriyama M., Ikeda I., Chiba A., Oshita F., Imaizumi A., Yamamoto H., Miyano H., Horimoto K., Tochikubo O., Mitsushima T., Yamakado M., Okamoto N. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 2011, 6(9):e24143.
49. Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet 2003, 361(9356):512-519.
50. Wedge D.C., Allwood J.W., Dunn W., Vaughan A.A., Simpson K., Brown M., Priest L., Blackhall F.H., Whetton A.D., Dive C., Goodacre R. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal. Chem. 2011, 83(17):6689-6697.
51. Ubhi B.K., Riley J.H., Shaw P.A., Lomas D.A., Tal-Singer R., MacNee W., Griffin J.L., Connor S.C. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur. Respir. J. 2012, 40(2):345-355.
52. Rodríguez D.A., Alcarraz-Vizán G., Díaz-Moralli S., Reed M., Gómez F.P., Falciani F., Günther U., Roca J., Cascante M. Plasma metabolic profile in COPD patients: effects of exercise and endurance training. Metabolomics 2012, 8:508-516.
53. Wang L., Tang Y., Liu S., Mao S., Ling Y., Liu D., He X., Wang X. Metabonomic profiling of serum and urine by 1H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PLoS ONE 2013, 8(6):e65675.
54. De Meyer T., Sinnaeve D., Van Gasse B., Rietzschel E.R., De Buyzere M.L., Langlois M.R., Bekaert S., Martins J.C., Van Criekinge W. Evaluation of standard and advanced preprocessing methods for the univariate analysis of blood serum 1 H-NMR spectra. Anal. Bioanal. Chem. 2010, 398(4):1781-1790.
55. Kohl S.M., Klein M.S., Hochrein J., Oefner P.J., Spang R., Gronwald W. State-of-the art data normalization methods improve NMR-based metabolomic analysis. Metabolomics 2012, 8(Suppl 1):S146-S160.
56. Smith C.B., Swanson S.J., Mhango G., Wisnivesky J.P. Survival after segmentectomy and wedge resection in stage I non-small-cell lung cancer. J. Thorac. Oncol. 2013, 8(1):73-78.
57. Heinzerling J.H., Kavanagh B., Timmerman R.D. Stereotactic ablative radiation therapy for primary lung tumors. Cancer J. 2011, 17(1):28-32.
58. Fan T.W., Lane A.N., Higashi R.M., Farag M.A., Gao H., Bousamra M., Miller D.M. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 2009, 8:41.
59. Bertini I., Cacciatore S., Jensen B.V., Schou J.V., Johansen J.S., Kruhøffer M., Luchinat C., Nielsen D.L., Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012, 72(1):356-364.
60. Torri G.M., Torri J., Gulian J.M., Vion-Dury J., Viout P., Cozzone P.J. Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases. Clin. Chim. Acta 1999, 279:77-96.
61. Bell J.D., Brown J.C., Nicholson J.K., Sadler P.J. Assignment of resonances for "acute-phase" glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987, 215(2):311-315.
62. Zira A.N., Theocharis S.E., Mitropoulos D., Migdalis V., Mikros E. 1H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J. Proteome Res. 2010, 9(8):4038-4044.
63. Dawiskiba T., Deja S., Mulak A., Zabek A., Jawień E., Pawełka D., Banasik M., Mastalerz-Migas A., Balcerzak W., Kaliszewski K., Skóra J., Barć P., Korta K., Pormańczuk K., Szyber P., Litarski A., Młynarz P. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J. Gastroenterol. 2014, 20(1):163-174.
64. Jobard E., Pontoizeau C., Blaise B.J., Bachelot T., Elena-Herrmann B., Trédan O. A serum nuclear resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 2014, 343(1):33-41.
65. Bonuccelli G., Tsirigos A., Whitaker-Menezes D., Pavlides S. Ketones and lactate fuel tumor growth and metastasis. Cell Cycle 2010, 9(17):3506-3514.